Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Revenues Drop 14 Percent, Loss Narrows in Q1

NEW YORK, May 17 (GenomeWeb News) - Transgenomic today reported a 14-percent dip in revenues but a narrowed loss for the first quarter of 2005.

 

The company's revenues in the quarter receded to $7.4 million from $8.6 million during the year-ago period. While revenues from its BioSystems segment climbed 8 percent, to $6.9 million, revenues from the Nucleic Acids segment dropped 80 percent, to $400,000. This decrease is consistent with the company's exist from oligonucleotide manufacturing last year, according to a company statement.

 

Research and development costs dropped to $606,000 from $1.9 million during last year's first quarter.

 

The company's net loss narrowed to $2.9 million, or $.1 per share, down from $3.9 million, or $.13 per share, during the same quarter in 2004.

 

As of March 31, Transgenomic had $1.5 million in cash, cash equivalents, and short-term investments.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.